Coverage With Evidence Development: Planning For Reimbursement On CMS’ Shifting Playing Field
This article was originally published in The Gray Sheet
You may also be interested in...
Double Duty: Creating Trials To Satisfy Both FDA And CMS
Firms can do "double duty" by gathering economic data during their FDA pivotal trials to get a jump start on CMS coverage, according to Abbott Diagnostic's Barbara Calvert, director of medical products reimbursement
Double Duty: Creating Trials To Satisfy Both FDA And CMS
Firms can do "double duty" by gathering economic data during their FDA pivotal trials to get a jump start on CMS coverage, according to Abbott Diagnostic's Barbara Calvert, director of medical products reimbursement
Informed Consent Issues Proving Tricky In CMS Evidence-Development Policy
Issues surrounding informed consent appear to be complicating CMS' efforts to finalize a policy allowing it to require evidence collection as a condition of national Medicare coverage